BSXNYSE$57.6164

BOSTON SCIENTIFIC CORP

Advanced Medical Equipment & TechnologyVerified

BOSTON SCIENTIFIC CORP (BSX) is currently classified as Advanced Medical Equipment & Technology within Advanced Medical Equipment & Technology (Healthcare). Classification confidence: 0.92 (verified market data). Capital structure on the latest snapshot: total assets 43,673,000,000 USD, total equity 24,233,000,000, short-term debt 0, long-term debt 11,137,000,000. Net cash position is approximately -9,172,000,000 USD. Self-calculated market cap is 86,098,145,000 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 20,074,000,000, gross profit 13,854,000,000, operating income 3,613,000,000, net income 0. Risk profile from automated assessment: liquidity risk medium, dilution risk medium. Flags: Net cash is negative after subtracting total debt.; Source documents mention dilution or offering risk..

30-day price · BSX-12.64 (-18.4%)

Low$52.52High$71.49Close$55.96As of18 May, 00:00 UTC

Profile

CompanyBOSTON SCIENTIFIC CORP

ExchangeNYSE

TickerBSX

CIK0000885725

SICSurgical & Medical Instruments & Apparatus

SectorHealthcare

BusinessHealthcare Services & Equipment

Industry groupHealthcare Services & Equipment

IndustryAdvanced Medical Equipment & Technology

AI analysis

Business. BOSTON SCIENTIFIC CORP is classified under Healthcare / Advanced Medical Equipment & Technology and appears not currently profitable on the latest normalized snapshot.

Classification. Classification confidence is 0.92 based on verified market data; matched terms: Advanced Medical Equipment & Technology, Healthcare Services & Equipment, Healthcare.

Key takeaways

Debt to equity is about 0.46x.
Our research and development efforts are focused largely on the development of next-generation and novel technology offerings across multiple programs and all divisions.
Analyst estimate: Mean price target = 87.39 USD

Financial snapshot

PeriodFY2025

CurrencyUSD

Revenue$20.07B

Gross profit$13.85B

Operating income$3.61B

Net income—

R&D—

SG&A—

D&A$1.37B

SBC$299.0M

Operating cash flow$4.53B

CapEx$876.0M

Free cash flow$3.66B

Total assets$43.67B

Total liabilities—

Total equity$24.23B

Cash & equivalents$1.97B

Long-term debt$11.14B

Annual history (last 5)

PeriodRevenueOp IncomeNet IncomeFCF

FY2025$20.07B$3.61B—$3.66B

FY2024$16.75B$2.60B—$2.65B

FY2025$16.75B$2.60B—$2.65B

FY2023$14.24B$2.34B—$1.79B

FY2024$14.24B$2.34B—$1.79B

PeriodGross %Op %Net %FCF %

FY2025————

FY2024————

FY2025————

FY2023————

FY2024————

PeriodAssetsEquityCashDebt

FY2025$43.67B$24.23B$1.97B—

FY2024$39.40B$21.77B$414.0M—

FY2025$39.40B$21.77B$414.0M—

FY2023$35.14B$19.28B$865.0M—

FY2024$35.14B$19.28B$865.0M—

PeriodOCFCapExFCFSBC

FY2025$4.53B$876.0M$3.66B$299.0M

FY2024$3.44B$790.0M$2.65B$266.0M

FY2025$3.44B$790.0M$2.65B$266.0M

FY2023$2.50B$711.0M$1.79B$233.0M

FY2024$2.50B$711.0M$1.79B$233.0M

Quarterly history (last 4)

PeriodRevenueOp IncomeNet IncomeFCF

Q3 2025$14.79B$2.79B—$2.65B

Q2 2025$9.72B$1.74B—$1.48B

Q1 2025$4.66B$921.0M—$354.0M

Q1 2025————

PeriodGross %Op %Net %FCF %

Q3 2025————

Q2 2025————

Q1 2025————

PeriodAssetsEquityCashDebt

Q3 2025$42.71B$23.39B$1.27B—

Q2 2025$41.56B$22.42B$534.0M—

Q1 2025$40.14B$22.21B$725.0M—

Q1 2025$39.40B$21.77B$414.0M—

PeriodOCFCapExFCFSBC

Q3 2025$3.17B$525.0M$2.65B$228.0M

Q2 2025$1.83B$344.0M$1.48B$149.0M

Q1 2025$541.0M$187.0M$354.0M$74.0M

Q1 2025————

Valuation

Market price$57.61

Market cap$86.10B

Enterprise value$95.27B

P/E—

Reported non-GAAP P/E—

EV/Revenue4.8

EV/Op income26.4

EV/OCF21.0

P/B—

P/Tangible book—

Tangible book—

Net cash-$9.17B

Current ratio1.6

Debt/Equity0.5

ROA—

ROE—

Cash conversion—

CapEx/Revenue4.4%

SBC/Revenue1.5%

Asset intensity0.1

Dilution ratio—

Risk assessment

Dilution riskMedium

Liquidity riskMedium

Net cash is negative after subtracting total debt.
Source documents mention dilution or offering risk.

Industry benchmarks

Activity: Advanced Medical Equipment & Technology · cohort 3 companies

MetricBSXActivity

Op margin18.0%19.4% medp25 17.8% · p75 22.0%below median

Net margin—17.7% medp25 16.4% · p75 19.0%

Gross margin69.0%73.5% medp25 71.3% · p75 75.8%bottom quartile

R&D / revenue—6.2% medp25 4.7% · p75 12.0%

CapEx / revenue4.4%4.3% medp25 3.9% · p75 4.3%top quartile

Debt / equity46.0%41.5% medp25 29.2% · p75 51.3%above median

Observations

IR observations

Mean price target87.39 USD

Median price target85.50 USD

High price target118.00 USD

Low price target60.00 USD

Mean recommendation1.78 (1=strong buy, 5=strong sell)

Strong-buy count12.00

Buy count21.00

Hold count4.00

Sell count0.00

Strong-sell count0.00

Mean EPS estimate3.38 USD

Last actual EPS3.06 USD

Source data

Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.

SEC filingstype companyfacts · CIK 0000885725 · 746 us-gaap concepts

data.sec.gov/CIK0000885725.json

2026-05-01 03:43 UTC#f255a308

Market quoteclose USD 57.61 · shares 1.49B diluted

no public URL

2026-05-01 03:43 UTC#1b6cd24b

Source: analysis-pipeline (hybrid)Generated: 2026-05-01 03:44 UTCJob: 4b3bcd23